🇺🇸 FDA
Patent

US 12377106

Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK

granted A61KA61K31/497A61K31/506

Quick answer

US patent 12377106 (Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK) held by NURIX THERAPEUTICS, INC. expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
NURIX THERAPEUTICS, INC.
Grant date
Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/497, A61K31/506, A61K31/5377, A61K9/0053